Inclusion Criteria:  Patients who have completed the Screening Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA type restriction combination is available in Ziopharm's TCR library.  Patients who have previously received at least one line of standard systemic therapy for their advanced cancer and have either progressed or have recurred. Specifically:  Cohort 1: Gynecologic cancers (i.e., ovarian, endometrial):  Ovarian cancer: Subjects who are platinum-resistant, as defined by progression on a platinum-containing regimen or within 6 months of a previous platinum dose. Endometrial cancer: Subjects who have received at least 2 prior lines of therapy for advanced/recurrent disease (including adjuvant chemotherapy and adjuvant chemo-radiation therapy). Prior hormonal therapy will not count towards prior lines of therapy. Cohort 2: Metastatic colorectal cancer: Subjects with colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, irinotecan- , anti-VEGF, and/or anti-EGFR containing chemotherapy; Subjects with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer should have received a checkpoint inhibitor such as pembrolizumab or nivolumab. Cohort 3: Pancreatic cancer: Subjects who have progressive disease after receiving initial treatment with FOLFOX, (modified) FOLFIRINOX, and/or a gemcitabine-based therapy. Cohort 4: Non-small cell lung cancer (NSCLC): Subjects with recurrent and/or metastatic disease who have disease progression after treatment with a PD-1/PD-L1 inhibitor either as a single-agent or in combination with other checkpoint inhibitors (e.g., CTLA-4 inhibitors) and/or chemotherapy. Subjects with targetable oncogene alterations (e.g., EGFR, ALK, ROS1, RET, MET, NTRK1-3, BRAF) must have had disease progression on at least one prior line of targeted therapy. Cohort 5: Cholangiocarcinoma: Subjects who have received at least one line of standard therapy. Subjects with targetable oncogene alterations (e.g., BRAF, FGFR2, HER2) shall have had disease progression on at least one prior line of targeted therapy. Patients must have evaluable or measurable disease per RECIST 1.1. Patients must be able to provide written informed consent. Patients must be age > 18 years and < 75 years. Patients with 3 or fewer brain metastases that are < 1 cm in diameter and asymptomatic are eligible. Patients who have been treated with radiotherapy to the CNS must be clinically stable 14 days after completing treatment for the patient to be eligible. Focal radiotherapy for treatment of cranial or spinal bone metastases is acceptable. Patients with surgically resected brain metastases are eligible. Clinical Performance Status of ECOG 0 or 1. Patient must be willing and able to provide written informed consent for the long-term follow-up (LTFU) gene therapy study (TCR001-202) for up to 15 years post treatment per FDA requirements. Adequate bone marrow reserve Adequate major organ system function Patients may have undergone minor surgical procedures or limited-field radiotherapy provided any major organ toxicities have recovered to ≤ Grade 1. Female of child-bearing potential and sexually active male subjects must agree to practice highly effective contraception prior to the start of the first treatment, during the study, and for at least 4 months after the last dose. Highly effective contraceptive measures include stable use of combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal, transdermal) or progestogen-only hormonal contraception (oral, injectable, implantable) associated with inhibition of ovulation initiated 2 or more menstrual cycles prior to screening; intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal ligation; vasectomized partner; and or sexual abstinence**. Lung Cancer subjects only: More than two weeks must have elapsed since any prior palliation for major bronchial occlusion or bleeding and enrollment, and patient's toxicities must have recovered to < Grade 1.  Exclusion Criteria:  Positive beta-HCG in female of child-bearing potential defined as not post-menopausal for 12 months or no previous surgical sterilization or lactating females. Concurrent systemic steroid therapy at a dose of >10 mg prednisone daily or equivalent is excluded. Physiologic dosing of steroids to treat adrenal insufficiency is permitted. Topical or inhaled steroids are permitted. Active systemic infections requiring anti-infective treatment, coagulation disorders or any other active or uncompensated major medical illnesses. Any form of primary immunodeficiency (such as severe combined immunodeficiency disease). Concurrent opportunistic infections. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, or aldesleukin. Uncontrolled cardiac conditions, as determined by resting ECG or as judged by the investigator. Severe chronic respiratory condition as determined by the following: History of a bleeding disorder or unexplained major bleeding diathesis or is currently receiving chronic anticoagulation therapy. Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the subjects' ability to tolerate high-dose aldesleukin; (please note: at the discretion of the PI, subjects enrolled in cohort 4 (NSCLC) may receive low-dose aldesleukin). Lung cancer patients only: any major bronchial occlusion or bleeding not amenable to palliation. Patients with a second active invasive cancer if it may confound assessment of response to the current therapy. Patients with psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.